Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta
By Chris Wack
Vir Biotechnology said the U.S. Food and Drug Administration has cleared its investigational new drug application and granted Fast Track designation for the combination of tobevibart and elebsiran to treat chronic hepatitis delta infection.
The company said tobevibart and elebsiran are currently being evaluated in its Phase 2 hepatitis delta clinical trial. Complete 24-week treatment data is on track to be reported in the fourth quarter.
The FDA's Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
In June, Vir reported preliminary Phase 2 trial data which suggested treatment with tobevibart alone or in combination with elebsiran was generally well tolerated, and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 26, 2024 08:51 ET (12:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now